Personalis, Inc. (NasdaqGM: PSNL)
Health Care · Life Sciences Tools & Services · US
$16.00
-0.37% today · +85.8% 1Y
Personalis, Inc. (NasdaqGM: PSNL) operates in the Life Sciences Tools & Services industry within the Health Care sector. The company is valued at $1.71B and employs 260 people.
Over the last twelve months the share price has gained 85.8%, trading between 4.96 and 18.89.
Tweenvest scores Personalis, Inc. across four factors: quality 40/100, value 56/100, growth 54/100. Its strongest factor is value.
PSNL price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.71B
- Revenue (TTM)
- $69.67M
- P/E
- —
- EPS
- -1.10
- Dividend yield
- —
- Beta (5Y)
- 2.32
- 52-week high
- $18.89
- 52-week low
- $4.96
- Avg volume (3M)
- —
- Shares outstanding
- 106.80M
- Employees
- 260
- Next earnings
- —
About Personalis, Inc.
Personalis, Inc. operates globally as a specialized cancer genomics firm. The company delivers advanced sequencing and data analysis capabilities, primarily supporting the development of novel cancer treatments and facilitating extensive genetic research initiatives. Central to their offerings is the NeXT Platform, which enables detailed data analysis of tumors and their surrounding immune microenvironments, even from small tissue or plasma samples. This platform encompasses several specialized solutions: ImmunoID Next for tissue-based tumor profiling; NeXT Liquid Biopsy for plasma analysis; NeXT Personal, a specific liquid biopsy designed for individual patient tumor tracking; the NeXT Dx Test, a genomic cancer profiling tool that identifies composite biomarkers for treatment guidance; and the sophisticated NeXT SHERPA and NeXT NEOPS for predicting neoantigens. Additionally, Personalis offers the ACE platform, utilized for diverse clinical and therapeutic applications like neoantigen prediction, biomarker identification, and the selection of new drug targets. Their clientele includes biopharmaceutical companies, academic institutions, non-profit organizations, and government entities. The company has established significant partnerships with organizations such as Mayo Clinic, MapKure, LLC, SpringWorks Therapeutics, Inc., and Moores Cancer Center. Personalis, Inc. was founded in 2011 and is based in Menlo Park, California.
- ISIN
- US71535D1063
- Founded
- 2011
- Listed since
- Jun 20, 2019
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Life Sciences Tools & Services companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| SKAN Group AGSWX: SKAN | $1.91B | CHF70.70 | +0.57% |
| Suzhou Sepax Technologies Co., Ltd.SHSE: 688758 | $1.81B | CN¥29.06 | -3.55% |
| PolyPeptide Group AGSWX: PPGN | $1.74B | CHF43.85 | -0.57% |
| OneSource Specialty Pharma LimitedNSEI: ONESOURCE | $1.73B | Rs1,461.30 | -3.10% |
| Azenta, Inc.NasdaqGS: AZTA | $1.65B | $37.72 | +4.78% |
| Peptron, Inc.KOSDAQ: A087010 | $1.59B | ₩91,500.00 | -29.34% |
| ChemoMetec A/SCPSE: CHEMM | $1.51B | Dkr586.50 | +5.58% |
| Indegene LimitedNSEI: INDGN | $1.44B | Rs580.10 | -2.26% |
Figures last refreshed Oct 11, 2026.